Cancer treatments must now go beyond the usual concerns of patients who grapple with their high costs in favor of improving ...

That's what the analyst community seems to expect from Viking Therapeutics (NASDAQ: VKTX) in the foreseeable future. The ...

Researchers evaluated the association between the use of various hormonal contraceptives and the risk for surgically treated intracranial meningioma.

The agent, first approved in December for biweekly subcutaneous injection for EGFR-mutated NSCLC, showed similar efficacy and safety when administered monthly.

Zimbabwe is now one of the first countries in the world to start a lenacapavir program, which was made possible through funding from the United States government and The Global Fund.

Zimbabwe is one of the first countries to introduce the HIV prevention drug lenacapavir. The program aims to target over 46,000 high-risk individuals, backed by U.S. funding and the Global Fund.

By Chris Takudzwa Muronzi HARARE, Feb 19 (Reuters) - Zimbabwe's health authorities on Thursday began administering the long-acting HIV prevention drug lenacapavir, making the country one of the first ...

In the heart of Mississippi, Diana "Di" Fillhart, a vibrant 68-year-old, lives a life defined by purpose and an unwavering ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Health Canada has approved KEYTRUDA SC™ (pembrolizumab injection), a new subcutaneous formulation of ...

The development, researchers say, could fundamentally change how hypertension is managed, particularly at a time when control rates remain alarmingly low.

The FDA approved a once-monthly Rybrevant Faspro schedule with Lazcluze for first-line EGFR-mutated advanced NSCLC, reducing visits.

Phase 3 trial results show combined ixekizumab and tirzepatide therapy outperforms ixekizumab alone for patients with psoriasis and obesity or overweight.